Kelonia is pioneering a new wave of genetic medicines using its next generation gene delivery platform. The company’s simple and elegant cutting-edge in vivo gene delivery technology uses a few potent lentiviral vector-like particles to precisely and efficiently deliver in vivo genetic cargo to the desired target tissue, and only that tissue, every time. With an initial focus on developing transformational therapies for solid tumors and hematologic cancers, Kelonia is building a pipeline of genetic medicines for a wide range of diseases, with the bold goal of bringing genetic medicines to every patient in need.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $50M
Investors 1
| Date | Name | Website |
| 31.12.2022 | Alta Partn... | altapartne... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 28.04.2022 | Series A | $50M | Alta Partn... |
Mentions in press and media 4
| Date | Title | Description | Source |
| 15.03.2024 | Learn how Developments in Genetic Medicine are Improving Tre... | medical advancements Discover the latest innovations in therapeutic technology on an upcoming segmen... | prweb.com/... |
| 02.05.2022 | Kelonia Therapeutics Emerges with $50M to Deliver Precision ... | What You Should Know: – Kelonia Therapeutics, a Boston-based biotech company focused on vivo gene de... | hitconsult... |
| 29.04.2022 | Kelonia Therapeutics Raises $50M in Series A Financing | Kelonia Therapeutics, a Boston, MA-based biotech company focused on in vivo gene delivery, raised $5... | finsmes.co... |
| 28.04.2022 | Has Elon Musk already broken his merger agreement with Twitt... | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign ... | fortune.co... |